Literature DB >> 12643105

Combination oral agent and insulin therapy for type 2 diabetes mellitus.

M D Passaro1, R E Ratner.   

Abstract

Type 2 diabetes is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action. Over time, there is progressive beta-cell failure. Combination oral and insulin therapy aims at treating both the defects in underlying pathophysiology and replacing insulin once beta-cell failure has occurred. Combination therapy is routinely used in the management of diabetes to reduce hemoglobin A1c, weight gain, and the number of insulin injections a patient requires. This article examines the effects of combining various oral agents with insulin on glycemic control, hypoglycemia, weight gain, and nonglycemic benefits of these combinations.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 12643105     DOI： 10.1007/s11892-001-0021-y

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


  27 in total

1.  Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

Authors:  H Yki-Järvinen; A Dressler; M Ziemen
Journal:  Diabetes Care       Date:  2000-08       Impact factor: 19.112

2.  Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  M I Harris; K M Flegal; C C Cowie; M S Eberhardt; D E Goldstein; R R Little; H M Wiedmeyer; D D Byrd-Holt
Journal:  Diabetes Care       Date:  1998-04       Impact factor: 19.112

3.  Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

Authors:  S Schwartz; P Raskin; V Fonseca; J F Graveline
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

4.  Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.

Authors:  M Shichiri; H Kishikawa; Y Ohkubo; N Wake
Journal:  Diabetes Care       Date:  2000-04       Impact factor: 19.112

5.  Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients.

Authors:  V Fonseca; H L Foyt; K Shen; R Whitcomb
Journal:  Diabetes Care       Date:  2000-03       Impact factor: 19.112

6.  Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial.

Authors:  H Yki-Järvinen; L Ryysy; K Nikkilä; T Tulokas; R Vanamo; M Heikkilä
Journal:  Ann Intern Med       Date:  1999-03-02       Impact factor: 25.391

7.  Outcome of metformin-facilitated reinitiation of oral diabetic therapy in insulin-treated patients with non-insulin-dependent diabetes mellitus.

Authors:  D S Bell; M S Mayo
Journal:  Endocr Pract       Date:  1997 Mar-Apr       Impact factor: 3.443

8.  Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.

Authors:  J L Johnson; S L Wolf; U M Kabadi
Journal:  Arch Intern Med       Date:  1996-02-12

9.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Authors:  Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri
Journal:  Diabetes Res Clin Pract       Date:  1995-05       Impact factor: 5.602

10.  U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.

Authors: 
Journal:  Diabetes       Date:  1995-11       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.